A, D., JV, E., MRPT, M., HS, F., TM, Z., ML, C., & UF, M. (2020). Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Dove Medical Press.
Chicago Style (17th ed.) CitationA, David-Silva, Esteves JV, Morais MRPT, Freitas HS, Zorn TM, Correa-Giannella ML, and Machado UF. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Dove Medical Press, 2020.
MLA (8th ed.) CitationA, David-Silva, et al. Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice. Dove Medical Press, 2020.
Warning: These citations may not always be 100% accurate.